COVID 19
Conditions
Keywords
COVID 19 cognitive impairement
Brief summary
As COVID-19 pandemic is still ongoing, patients follow-up begins to reveal cognitive and psychological disorders. There are not yet well described, neither their physiopathology. This study will consist in the detection and characterization of cognitive and psychological impairments in young patients under 65 years of age who have been hospitalized more than 72 hours for a severe COVID-19 infection.
Detailed description
Initial consecutive screening of patients (\<65 years) hospitalized between the 01/10/2020 and the 01/07/2021 for more than 72 hours for COVID-19 infection in 6 hospitals of the East of France. If detection of cognitive complaints (QPC scale : Questionnaire of cognitive complaints), continuation of the study. Evaluation with cognitive assessments, morphological and functional imaging and EEG will be done at 9 ± 3 months and 2 years after initial hospitalisation. Data will be collected concerning social and professional outcome. An ancillary study will be conducted at the Nancy University Hospital. This ancillary study is entitled TRAUMA-COV: Screening and therapeutic proposal of post-traumatic sequelae in the aftermath of a severe Covid-19 in young subjects. The main objective of this study is to evaluate the incidence of post-Covid-19 post-traumatic disorders (post-traumatic stress disorder, psychogenic and somatoform dissociative tendency, neurological dissociative disorder) in a longitudinal way. This optional study will be offered to all patients from the main study who meet the selection criteria.
Interventions
DIAGNOSTIC_TESTCognitive assessment
Complete cognitive and psychological assessment
DIAGNOSTIC_TESTImaging
Brain MRI Optional: Brain FDG PET (Brain positron emission tomography with F-18 fluorodeoxyglucose)
DIAGNOSTIC_TESTRoutine care
Electroencephalogram (EEG) Optional: polysomnography, lumbar puncture
Psychiatric consultation if necessary
Sponsors
Centre Hospitalier Universitaire de Besancon
University Hospital, Strasbourg, France
Centre Hospitalier Régional Metz-Thionville
Centre hospitalier Epinal
Hopitaux Civils de Colmar
Central Hospital, Nancy, France
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patients between 18 and 65 years of age (at discharge of hospitalization), * Patient hospitalized for more than 72 hours (in intensive care or conventional sector) for a COVID-19 infection defined by a positive PCR (Polymerase Chain Reaction) test and/or typical aspect on thoracic scanner, * Patient discharged from hospital between 01/10/2020 and 01/04/2021, * Patient with suspected cognitive impairment (obtaining a pathologic QPC score) during the phone screening, * Patient having received complete information on the organization of the research and having given written informed consent (or a third person, independent of the investigator and the sponsor, in case of inability to read or write), * Patient affiliated with a social security plan or beneficiary of such a plan, * Patient with a sufficient level of written French comprehension to complete the cognitive assessment.
Exclusion criteria
* Inability to travel to perform the BNP or additional tests, * Contraindication to perform brain MRI (pacemaker, etc.), * Presence of chronic neurological diseases (multiple sclerosis, neurodegenerative disease, epilepsy) and/or major cognitive disorders (stroke, head trauma) pre-COVID-19, * Presence of psychiatric disorder historys (bipolar or psychotic illness) pre-COVID-19, * Patients with very extensive post-COVID-19 brain damage leading to impossibility to realise cognitive assessment, * Addictive history or comorbidities (alcoholism, drug use) with sequelae of cognitive impairment, * Persons covered by articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of cognitive and psychological disorders 1 year after COVID-19 infection | up to 1 year | Perfomance to cognitive assessment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of cognitive and psychological disorders 1 year and 2 years after COVID-19 infection | up to 2 years | Number of patients with confirmed cognitive and/or psychological disorder compared to the total number of patients who completed the QPC scale |
| Severity of cognitive and psychological disorders 1 year after COVID-19 infection | up to 1 year | Perfomance to cognitive assessment |
| Evaluate the prognosis of cognitive and psychological disorders at 2 years according to the proposed medical care | up to 2 years | Cognitive assessment |
Countries
France
Outcome results
None listed